Figure 3From: Is mTOR inhibition a systemic treatment for tuberous sclerosis?Progressive reduction of renal AMLs. A girl with a TSC2 mutation presented renal AMLs since childhood, with no impairment of renal function but with a progressivre growth both in number and in size. When she was 23Â years old Everolimus was started (A, baseline), with a progressive reduction in the total volume of lesions. Figure B is the MRI after 12Â weeks of treatment (76% of volume reduction), while figure C is after 144Â weeks of treatment with Everolimus (85% of volume reduction).Back to article page